Temus is proud to be the first in Asia to be appointed as an Illumina Connected Analytics (ICA) Implementation Partner. ICA is an integrated, secured data platform to operationalize informatics and drive scientific insights. It can also support third-party collaborators across analytical tools and genomics applications for research, clinical and industry partnerships. We look forward to our partnership with national healthcare and research platforms like A*STAR – Agency for Science, Technology and Research, to advance the development of omics solutions to build analytics pipelines and derive meaningful insights from next-generation sequencing data, and that they might fortify their bioinformatics resources through the use of innovative analytics solutions.
“This opportunity to work with Illumina as Singapore’s sole ICA Implementation Partner marks a significant milestone for Temus. Through our partnership with Bioinformatics Institute, A*STAR (BII) and ICA programme certification, we look forward to supporting global innovation in genomics software solutions. This work underscores our commitment to unlocking both economic and social impact, to advance healthcare research, education and decision-making with accessible cutting-edge solutions,” said KC Yeoh, Chief Executive Officer, Temus.
About Illumina Connected Software
Illumina Connected Analytics (ICA) is a secure genomic data platform that provides efficiency in processing, managing, and analyzing large volumes of sequencing data. Its robust integration with Illumina sequencing systems provides the ability to securely transfer data from the sequencer directly in real-time and automatically launch secondary analysis pipelines in the cloud. This helps to streamline the sequencing workflow, enabling bioinformaticians to focus on the analysis, aggregation & querying of results with interactive tools within ICA as opposed to having many different specialized personnel to build custom pipelines and automate the end-to-end process.
About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023, we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
